Profile
Sector:
HealthcareIndustry:
BiotechnologyCountry:
DenmarkIPO:
28 January 2015Website:
http://ascendispharma.comNext earnings report:
05 September 2024Last dividends:
N/ANext dividends:
N/APrice
regular market | Wed, 03 Jul 2024 17:00:01 GMTDividend
Analysts recommendations
Institutional Ownership
ASND Latest News
- 40% of efficacy-evaluable patients (2 out of 5) in the initial cohort of patients with anti-PD-1 refractory melanoma treated with TransCon IL-2 β/γ in combination with TransCon TLR7/8 Agonist exhibited confirmed clinical responses with no new safety signals
According to the FDA, Ascendis' submission of data for its hormone replacement therapy is considered a significant update to their previous submission. A decision is anticipated by August 14th.
Ascendis Pharma announced on Tuesday that the U.S. Food & Drug Administration has prolonged its evaluation of the company's treatment for adult patients with a hormone disorder.
Ascendis Pharma A/S (ASND) held its Q1 2024 Earnings Conference Call on May 2, 2024 at 4:30 PM ET. Present on the call were Tim Lee, Jan Mikkelsen, Scott Smith, Stina Singel, and Joe Kelly. Various analysts also participated in the call. The operator welcomed all participants to the conference call and reminded them that it was in a listen-only mode.
Ascendis Pharma A/S (Nasdaq: ASND) will release its first quarter 2024 financial results and give a business update on May 2, 2024, after the U.S. financial markets close. A conference call and live webcast will be held at 4:30 p.m. Eastern Time (ET) on the same day to discuss the results.
We have narrowed our search to five biotech stocks with strong potential for 2024. These are MOR, LEGN, ASND, EXEL and EXAS.
Does Ascendis Pharma A/S (ASND) have what it takes to be a top stock pick for momentum investors? Let's find out.
Here is how Ascendis Pharma A/S (ASND) and Autolus Therapeutics PLC Sponsored ADR (AUTL) have performed compared to their sector so far this year.
Ascendis Pharma A/S (ASND) Q4 2023 Earnings Call Transcript
Ascendis Pharma (ASND) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
- 1(current)
What type of business is Ascendis Pharma A/S?
Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.
What sector is Ascendis Pharma A/S in?
Ascendis Pharma A/S is in the Healthcare sector
What industry is Ascendis Pharma A/S in?
Ascendis Pharma A/S is in the Biotechnology industry
What country is Ascendis Pharma A/S from?
Ascendis Pharma A/S is headquartered in Denmark
When did Ascendis Pharma A/S go public?
Ascendis Pharma A/S initial public offering (IPO) was on 28 January 2015
What is Ascendis Pharma A/S website?
https://ascendispharma.com
Is Ascendis Pharma A/S in the S&P 500?
No, Ascendis Pharma A/S is not included in the S&P 500 index
Is Ascendis Pharma A/S in the NASDAQ 100?
No, Ascendis Pharma A/S is not included in the NASDAQ 100 index
Is Ascendis Pharma A/S in the Dow Jones?
No, Ascendis Pharma A/S is not included in the Dow Jones index
When does Ascendis Pharma A/S report earnings?
The next expected earnings date for Ascendis Pharma A/S is 05 September 2024